Access the full text.
Sign up today, get DeepDyve free for 14 days.
Pedro Magalhães, H. Lashuel (2022)Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
NPJ Parkinson's Disease, 8
L. Tönges, C. Buhmann, S. Klebe, J. Klucken, E. Kwon, T. Müller, D. Pedrosa, N. Schröter, P. Riederer, P. Lingor (2022)Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
Journal of Neural Transmission, 129
Stephan Klatt, J. Doecke, A. Roberts, B. Boughton, C. Masters, M. Horne, Blaine Roberts (2021)A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
NPJ Parkinson's Disease, 7
A. Gopinath, P. Mackie, Basil Hashimi, A. Buchanan, Aidan Smith, Rachel Bouchard, Gerry Shaw, M. Badov, Leila Saadatpour, A. Gittis, A. Ramirez-Zamora, M. Okun, W. Streit, P. Hashemi, Habibeh Khoshbouei (2022)DAT and TH expression marks human Parkinson’s disease in peripheral immune cells
NPJ Parkinson's Disease, 8
Jin Bu, Jin-song Liu, Kun Liu, Zhaohui Wang (2019)Diagnostic utility of gut α-synuclein in Parkinson’s disease: A systematic review and meta-analysis
Behavioural Brain Research, 364
C. Bridel, W. Wieringen, H. Zetterberg, B. Tijms, C. Teunissen, J. Álvarez-cermeño, U. Andreasson, M. Axelsson, David Bäckström, A. Bartoš, M. Bjerke, K. Blennow, A. Boxer, L. Brundin, J. Burman, T. Christensen, L. Fialová, L. Forsgren, J. Frederiksen, M. Gisslén, E. Gray, M. Gunnarsson, S. Hall, O. Hansson, M. Herbert, J. Jakobsson, Jan Jessen-Krut, S. Janelidze, G. Johannsson, M. Jonsson, L. Kappos, M. Khademi, M. Khalil, J. Kuhle, M. Landén, V. Leinonen, G. Logroscino, Ching-Hua Lu, J. Lycke, N. Magdalinou, A. Malaspina, N. Mattsson, L. Meeter, S. Mehta, S. Modvig, T. Olsson, R. Paterson, Josué Pérez-Santiago, F. Piehl, Y. Pijnenburg, Okko Pyykkö, O. Ragnarsson, J. Rojas, J. Christensen, L. Sandberg, Carole Scherling, J. Schott, F. Sellebjerg, I. Simone, Tobias Skillbäck, Morten Stilund, P. Sundström, A. Svenningsson, R. Tortelli, C. Tortorella, A. Trentini, M. Troiano, M. Turner, J. Swieten, Mattias Vågberg, M. Verbeek, L. Villar, P. Visser, A. Wallin, A. Weiss, C. Wikkelsø, E. Wild (2019)Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Giorgio Vivacqua, Matthew Mason, M. Bartolo, M. Wegrzynowicz, L. Calo’, D. Belvisi, A. Suppa, G. Fabbrini, A. Berardelli, M. Spillantini (2022)Salivary α‐Synuclein RT‐QuIC Correlates with Disease Severity in de novo Parkinson's Disease
Movement Disorders, 38
S. Prange, Hendrik Theis, Magdalena Banwinkler, T. Eimeren (2022)Molecular Imaging in Parkinsonian Disorders—What’s New and Hot?
Brain Sciences, 12
L. Niemann, S. Lezius, A. Maceski, D. Leppert, Catrin Englisch, E. Schwedhelm, T. Zeller, C. Gerloff, J. Kuhle, C. Choe (2021)Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Parkinsonism & related disorders, 90
P. Eusebi, D. Giannandrea, Leonardo Biscetti, I. Abraha, D. Chiasserini, M. Orso, P. Calabresi, L. Parnetti (2017)Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis
Movement Disorders, 32
D. Berg, P. Borghammer, S. Fereshtehnejad, S. Heinzel, Jacob Horsager, E. Schaeffer, R. Postuma (2021)Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Nature Reviews Neurology, 17
C. Chinopoulos (2019)Quantification of mitochondrial DNA from peripheral tissues: Limitations in predicting the severity of neurometabolic disorders and proposal of a novel diagnostic test.
Molecular aspects of medicine
I. Manna, A. Quattrone, Selene Benedittis, B. Vescio, E. Iaccino, A. Quattrone (2021)Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study.
Parkinsonism & related disorders, 93
Yihang Han, Di Wu, Yan-juan Wang, Jian Xie, Zhijun Zhang (2022)Skin alpha-synuclein deposit patterns: A predictor of Parkinson's disease subtypes
Iván Martínez-Valbuena, N. Visanji, D. Olszewska, M. Sousa, P. Bhakta, A. Vasilevskaya, Chloe Anastassiadis, M. Tartaglia, G. Kovacs, A. Lang (2022)Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease
Movement Disorders, 37
A. Grünewald, K. Rygiel, Philippa Hepplewhite, C. Morris, M. Picard, D. Turnbull (2016)Mitochondrial DNA Depletion in Respiratory Chain–Deficient Parkinson Disease Neurons
Annals of Neurology, 79
K. Tsukita, H. Sakamaki-Tsukita, Kanta Tanaka, T. Suenaga, R. Takahashi (2019)Value of in vivo α‐synuclein deposits in Parkinson's disease: A systematic review and meta‐analysis
Movement Disorders, 34
H. Jęśko, A. Lenkiewicz, A. Wilkaniec, A. Adamczyk (2019)The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Acta neurobiologiae experimentalis, 79 3
Á. Iranzo, S. Borrego, I. Vilaseca, Carles Martí, M. Serradell, R. Sánchez-Valle, G. Kovacs, F. Valldeoriola, C. Gaig, J. Santamaria, E. Tolosa, E. Gelpí (2018)&agr;-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder
Marie-Therese Mackmull, Luise Nagel, F. Sesterhenn, J. Muntel, Jan Grossbach, Patrick Stalder, R. Bruderer, L. Reiter, W. Berg, Natalie Souza, Andreas Beyer, P. Picotti (2022)Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker
Nature Structural & Molecular Biology, 29
C. Castellani, R. Longchamps, Jing Sun, E. Guallar, D. Arking (2020)Thinking outside the nucleus: mitochondrial DNA copy number in health and disease.
Dong Wang, Zongchang Li, Weiqing Liu, Jun Zhou, Xiaoqian Ma, Jinsong Tang, Xiaogang Chen (2018)Differential mitochondrial DNA copy number in three mood states of bipolar disorder
BMC Psychiatry, 18
Whitley Aamodt, Teresa Waligórska, Junchao Shen, T. Tropea, A. Siderowf, D. Weintraub, M. Grossman, D. Irwin, D. Wolk, S. Xie, J. Trojanowski, L. Shaw, A. Chen-Plotkin (2021)Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease
Movement Disorders, 36
N. Magdalinou, R. Paterson, J. Schott, Nick Fox, C. Mummery, K. Blennow, K. Bhatia, H. Morris, P. Giunti, T. Warner, R. Silva, A. Lees, H. Zetterberg (2015)A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
Journal of Neurology, Neurosurgery & Psychiatry, 86
Yumei Liu, Kaixin Dou, Ling Xue, Xiaoyuan Li, A. Xie (2022)Neurofilament light as a biomarker for motor decline in Parkinson’s disease
Frontiers in Neuroscience, 16
Hanwen Zhang, Longping Yao, Zijian Zheng, Sumeyye Koc, Guohui Lu (2022)The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement
C. Starhof, MD Hejl, PhD Md, MD Carlsen, PhD Burton, K. PhD (2018)The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes
Haixia Ding, Zhen Huang, Mengjie Chen, Cheng Wang, X. Chen, Jiangning Chen, Junfeng Zhang (2016)Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease.
Parkinsonism & related disorders, 22
A. Delbarba, G. Abate, C. Prandelli, M. Marziano, L. Buizza, N. Varas, A. Novelli, F. Cuetos, C. Martínez, C. Lanni, M. Memo, D. Uberti (2016)Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients
Oxidative Medicine and Cellular Longevity, 2016
B. Mollenhauer, M. Dakna, N. Kruse, D. Galasko, T. Foroud, H. Zetterberg, Sebastian Schade, Roland Gera, Wenting Wang, Feng Gao, M. Frasier, L. Chahine, C. Coffey, A. Singleton, T. Simuni, D. Weintraub, J. Seibyl, A. Toga, C. Tanner, K. Kieburtz, K. Marek, A. Siderowf, J. Cedarbaum, S. Hutten, C. Trenkwalder, Danielle Graham (2020)Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
Movement disorders : official journal of the Movement Disorder Society, 35
T. Schirinzi, I. Salvatori, Henri Zenuni, Piergiorgio Grillo, C. Valle, G. Martella, N. Mercuri, A. Ferri (2022)Pattern of Mitochondrial Respiration in Peripheral Blood Cells of Patients with Parkinson’s Disease
International Journal of Molecular Sciences, 23
L. Oliveira, T. Gasser, R. Edwards, M. Zweckstetter, R. Melki, L. Stefanis, H. Lashuel, D. Sulzer, K. Vekrellis, G. Halliday, J. Tomlinson, M. Schlossmacher, P. Jensen, J. Schulze-Hentrich, O. Riess, W. Hirst, O. El‐Agnaf, B. Mollenhauer, Peter Lansbury, T. Outeiro (2021)Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
NPJ Parkinson's Disease, 7
Jean-Ha Baek, D. Mamula, Beata Tingstam, Marcela Pereira, Yachao He, P. Svenningsson (2019)GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson’s Disease Patients
Frontiers in Neuroscience, 13
J. Hoozemans, E. Haastert, P. Eikelenboom, R. Vos, J. Rozemuller, W. Scheper (2007)Activation of the unfolded protein response in Parkinson's disease.
Biochemical and biophysical research communications, 354 3
R. Barbour, Kristin Kling, John Anderson, Kelly Banducci, Tracy Cole, L. Diep, Michael Fox, J. Goldstein, F. Soriano, P. Seubert, T. Chilcote (2008)Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood
Neurodegenerative Diseases, 5
M. Funayama, K. Nishioka, Yuanzhe Li, N. Hattori (2022)Molecular genetics of Parkinson’s disease: Contributions and global trends
Journal of Human Genetics, 68
A. Evinova, Z. Hatokova, Z. Tatarkova, Mária Brodňanová, K. Dibdiaková, P. Račay (2022)Endoplasmic reticulum stress induces mitochondrial dysfunction but not mitochondrial unfolded protein response in SH-SY5Y cells
Molecular and Cellular Biochemistry, 477
K. Mnich, S. Moghaddam, P. Browne, T. Counihan, S. Fitzgerald, K. Martin, C. Richardson, A. Samali, A. Gorman (2022)Endoplasmic Reticulum Stress-Regulated Chaperones as a Serum Biomarker Panel for Parkinson’s Disease
Molecular Neurobiology, 60
H. Uwatoko, Yuka Hama, I. Iwata, S. Shirai, M. Matsushima, I. Yabe, Jun Utsumi, H. Sasaki (2019)Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson’s disease
Molecular Brain, 12
K. Doppler, Hanna-Maria Jentschke, L. Schulmeyer, D. Vadász, A. Janzen, M. Luster, H. Höffken, G. Mayer, J. Brumberg, J. Booij, T. Musacchio, S. Klebe, Elisabeth Sittig-Wiegand, J. Volkmann, C. Sommer, W. Oertel (2017)Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease
Acta Neuropathologica, 133
L. Oosterveld, Inge Verberk, N. Majbour, O. El‐Agnaf, H. Weinstein, H. Berendse, C. Teunissen, W. Berg (2019)CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
Movement Disorders, 35
I. Poggiolini, Vandana Gupta, M. Lawton, S. Lee, A. El-Turabi, Agustin Querejeta-Coma, C. Trenkwalder, F. Sixel-Döring, A. Foubert-Samier, A. Traon, G. Plazzi, F. Biscarini, J. Montplaisir, J. Gagnon, R. Postuma, E. Antelmi, W. Meissner, B. Mollenhauer, Y. Ben-Shlomo, M. Hu, L. Parkkinen (2021)Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
Zerui Wang, K. Becker, V. Donadio, S. Siedlak, Jue Yuan, M. Rezaee, A. Incensi, A. Kuzkina, C. Orrú, C. Tatsuoka, R. Liguori, S. Gunzler, B. Caughey, M. Jiménez-Capdeville, Xiongwei Zhu, K. Doppler, Li Cui, Shu Chen, Jiyan Ma, W. Zou (2020)Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
JAMA Neurology, 78
A. Pyle, Haidyan Anugrha, M. Kurzawa-Akanbi, A. Yarnall, D. Burn, G. Hudson (2016)Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease
Neurobiology of Aging, 38
Tainá Marques, H. Kuiperij, Ilona Bruinsma, A. Rumund, M. Aerts, R. Esselink, B. Bloem, M. Verbeek (2016)MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy
Molecular Neurobiology, 54
M. Goedert, M. Spillantini, K. Tredici, H. Braak (2013)100 years of Lewy pathology
Nature Reviews Neurology, 9
Madison Francis, M. Badov, G. Shaw, A. Collins, Douglas Miller, Carissa Hansen, P. Mackie, M. Tansey, A. Dagra, Irina Madorsky, A. Ramirez-Zamora, M. Okun, W. Streit, A. Gopinath, Habibeh Khoshbouei (2021)TNFα increases tyrosine hydroxylase expression in human monocytes
npj Parkinson's Disease, 7
Upasana Ganguly, Sukh Singh, Soumya Pal, Suvarna Prasad, B. Agrawal, R. Saini, S. Chakrabarti (2021)Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough
Frontiers in Aging Neuroscience, 13
Christina Toomey, W. Heywood, James Evans, Joanne Lachica, S. Pressey, Sandrine Foti, Mesfer Shahrani, Karishma D'Sa, I. Hargreaves, S. Heales, M. Orford, C. Troakes, J. Attems, E. Gelpí, M. Palkovits, T. Lashley, S. Gentleman, T. Révész, K. Mills, S. Gandhi (2022)Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s
Acta Neuropathologica Communications, 10
L. Stefanis (2012)α-Synuclein in Parkinson's disease.
Cold Spring Harbor perspectives in medicine, 2 2
Chunchen Xiang, Shengri Cong, X. Tan, Shuang Ma, Yang Liu, Hailong Wang, Shuyan Cong (2022)A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
NPJ Parkinson's Disease, 8
AbstractParkinson’s disease (PD) is a chronic neurodegenerative disorder that is clinically manifested by motor and non-motor symptoms. At the early stage of the disease, it can be misdiagnosed with some neurologic disorders due to overlapping or similar clinical features. In addition, the pathogenesis of this disease is initiated several years prior to the appearance of classical motor symptoms. This latent phase of neurodegeneration in PD characterised at cellular level by preservation of significant fraction of dopaminergic neurones is of particular interest with respect to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease with an aim to slow down or reverse the disease progression. Therefore, huge effort was performed in order to find and validate a biomarker that would reliably differentiate PD from other neurologic diseases as well as a biomarker that would reveal preclinical/prodromal stage of PD. This short review summarises a recent progress in validation of molecular biomarkers of PD, distinct from genetic markers of PD, with some focus on new analysed tissues and new methods.
Acta Medica Martiniana – de Gruyter
Published: Apr 1, 2023
Keywords: Parkinson’s disease; neurodegeneration; biomarker
Access the full text.
Sign up today, get DeepDyve free for 14 days.